Venture Visionary Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Venture Visionary Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-10,000	Closed	-$166K	–	572
2024 Q3	$166K	Sell	10,000 -1,000	-9%	-$17.3K	0.01%	525
2024 Q2	$211K	Sell	11,000 -700	-6%	-$14K	0.01%	518
2024 Q1	$277K	Buy	11,700 +1,700	+17%	+$34.5K	0.01%	465
2023 Q4	$112K	Hold	10,000	–	–	0.01%	505
2023 Q3	$92.5K	Hold	10,000	–	–	0.01%	490
2023 Q2	$119K	Buy	+10,000	New	+$133K	0.01%	503

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Venture Visionary Partners's NAMS Position: Q4 2024 in Review

Venture Visionary Partners sold out of NewAmsterdam Pharma (NAMS) in Q4 2024, closing a stake of 10,000 shares — an estimated $166K sold.

Venture Visionary Partners first reported a position in NAMS in Q2 2023 and held it in 6 quarters. The position peaked at $277K in Q1 2024. 130 funds tracked by Wall St. Rank hold NAMS as of Q4 2024.

Venture Visionary Partners reported no remaining NewAmsterdam Pharma position as of Q4 2024 after selling out during the quarter.
Venture Visionary Partners sold 10,000 NewAmsterdam Pharma shares in Q4 2024, an estimated $166K.
Venture Visionary Partners first reported a position in NewAmsterdam Pharma in Q2 2023 and held it in 6 quarters.
Venture Visionary Partners's NewAmsterdam Pharma position peaked at $277K in Q1 2024.
130 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q4 2024.

Based on Venture Visionary Partners's 13F filing for Q4 2024, filed 12 Feb 2025.